219 results
Page 5 of 11
6-K
EX-99.1
urr dr2dt7paj8k
6 Jan 21
Report of Foreign Private Issuer
10:06am
6-K
EX-99.1
g3cq43wb8z g90d7r4cy
10 Dec 20
Report of Foreign Private Issuer
8:19am
6-K
EX-99.2
5v4tr4tnnnku
10 Dec 20
Report of Foreign Private Issuer
8:19am
6-K
EX-99.1
ybbbkhdf529trjpzs0
12 Nov 20
1 Corporate Presentation | November 2020
8:36am
6-K
EX-99.1
ry792aoaieo0n1sar
9 Nov 20
Report of Foreign Private Issuer
7:31am
6-K
EX-99.1
zc9y8
27 Oct 20
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
10:27am
6-K
a3r1yc tnch
22 Oct 20
Notice of Annual General Meeting of Shareholders
4:10pm
6-K
EX-99.1
4521je p2
16 Oct 20
New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference
3:02pm
6-K
EX-99.1
zafh9e3fe n9
8 Sep 20
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
7:44am
6-K
EX-99.1
qp0bytqap zmj17n6
17 Aug 20
Report of Foreign Private Issuer
6:07am
6-K
EX-99.1
9gwpv
12 Aug 20
Kitov Pharma Announces ADS Ratio Change
4:52pm
6-K
EX-99.1
qug2dn
11 Aug 20
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results
8:22am
POS AM
lmor yvwi9b
10 Jul 20
Prospectus update (post-effective amendment)
4:35pm
F-3
gchxq elzmv
10 Jul 20
Shelf registration (foreign)
4:31pm
6-K
EX-99.1
g7kqw wy3k90
9 Jul 20
Kitov Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
7:31am
6-K
EX-99.1
vjb18wn03zmzkil
8 Jul 20
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody
7:31am
6-K
5d6tetmv3pc2c33q
2 Jul 20
Extraordinary General Meeting of Shareholders
4:19pm
6-K
EX-99.1
b9qv914h
2 Jul 20
Kitov Pharma Issues CEO Shareholder Letter Providing Business Update
8:35am
6-K
vcl3mrxedz a8t
1 Jul 20
Notice of Extraordinary General Meeting of Shareholders
4:50pm
6-K
EX-99.1
1qh9qz4r1w cv2e4x
25 Jun 20
Kitov Closes $35.0 Million Registered Direct Offering
4:30pm